Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2969530
Reference Type
Journal Article
Subtype
Review
Title
L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia
Author(s)
Kumar, K; Kaur, J; Walia, S; Pathak, T; Aggarwal, D
Year
2014
Is Peer Reviewed?
1
Journal
Leukemia and Lymphoma
ISSN:
1042-8194
Volume
55
Issue
2
Page Numbers
256-262
Language
English
PMID
23662993
DOI
10.3109/10428194.2013.803224
Web of Science Id
WOS:000330733100007
Abstract
L-asparaginase (L-ASNase) is an enzyme used most effectively in the treatment of acute lymphoblastic leukemia (ALL) for more than 30 years. It catalyzes the hydrolysis of amino acid l-asparagine to aspartic acid and ammonia, which leads to cell death. Clinical trials have been conducted using L-ASNase in combination with other drugs and radiotherapy, which have led to great success in the treatment of ALL. Treatments consist of induction therapy and central nervous system therapy. The achievement of complete remission in patients is associated with a few side-effects of using L-asparaginase, including pancreatitis, coagulation abnormalities and allergic reactions. Sometimes tumor cells may develop resistance to L-ASNase. To overcome these difficulties, the drug is modified by pegylation or immobilization, and also treatment protocols can be modified to increase the efficiency of the drug.
Keywords
Lymphocytes; lymphoid leukemia; myeloma
Tags
IRIS
•
Ammonia
Literature Search Update – Sept 2015 (private)
Literature Search Results
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity